Quipt Home Medical stock price target raised to $2.30 from $1.70 at Canaccord

Quipt Home Medical Corp. (QIPT) saw its price target raised by Canaccord Genuity to $2.30 from $1.70, though the firm maintained a Hold rating following mixed Q3 results that showed sequential improvement despite year-over-year declines, alongside a robust 72.5% gross margin. The company expanded its Midwest presence via a $17-18 million joint venture for a 60% stake in Hart Medical, marking its second recent health system partnership. However, Canaccord highlighted that Quipt's $41.1 million EBITDA is not translating to cash generation due to ongoing patient capital expenditures for Philips ventilator replacements, a headwind expected to persist into early 2026.

Analysis

Quipt Home Medical Corp. (QIPT) presents a mixed operational picture, as highlighted by Canaccord Genuity's decision to raise its price target to $2.30 while maintaining a Hold rating. The new target remains substantially below the $4.50 analyst consensus. The company's third-quarter results showed sequential improvement, featuring a robust 72.5% gross margin and EBITDA of $41.1 million, though this was offset by year-over-year declines and headwinds from a Humana contract and a non-renewed supply agreement. A critical issue is the disconnect between EBITDA performance and cash generation, attributed directly to significant patient capital expenditures for replacing Philips ventilators following a recall, a drag expected to persist into early 2026. Strategically, Quipt is actively pursuing growth through acquisitions, recently establishing a presence in Michigan and northern Ohio by acquiring a 60% stake in Hart Medical for approximately $17-18 million. This marks its second health system partnership, with management anticipating margin alignment from these new ventures within three quarters post-closing.

Key Decisions for Investors

• Investors should closely monitor Quipt's free cash flow conversion over the next several quarters, as the primary risk identified is the sustained negative impact of Philips ventilator replacement capex on cash generation through early 2026.
• The success of the company's M&A strategy is a key catalyst, so tracking the margin performance and integration of the newly acquired Hart Medical and Ballad Health businesses will be crucial to validate the growth thesis.
• Given the substantial gap between the current stock price, Canaccord's target, and the average analyst target, investors should weigh the potential valuation upside against the well-defined, medium-term cash flow headwinds before adjusting their positions.